Zobrazeno 1 - 10 of 140 pro vyhledávání: '"Michel, Demeule"'
2
Akademický článek
Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing
Autor: Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Véronique Lullier, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Frontiers in Immunology, Vol 15 (2024)
The anticancer efficacy of Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate internalized through a sortilin-mediated process, was assessed in a triple-negative breast cancer-derived MDA-MB-231 immunocompromised xenograft tumor model where
Externí odkaz: https://doaj.org/article/406adb6e515441f688e79a799ed206ee
Zobrazit plný text záznamu
3
Akademický článek
New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells
Autor: Cyndia Charfi, Michel Demeule, Jean-Christophe Currie, Alain Larocque, Alain Zgheib, Bogdan Alexandru Danalache, Amira Ouanouki, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Frontiers in Oncology, Vol 11 (2021)
Vasculogenic mimicry (VM) is defined as the formation of microvascular channels by genetically deregulated cancer cells and is often associated with high tumor grade and cancer therapy resistance. This microcirculation system, independent of endothel
Externí odkaz: https://doaj.org/article/9856283e5a394452a64411b0a22a4d2f
Zobrazit plný text záznamu
4
Akademický článek
The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells
Autor: Michel Demeule, Cyndia Charfi, Jean-Christophe Currie, Alain Zgheib, Bogdan Alexandru Danalache, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Pharmaceutics, Vol 14, Iss 9, p 1910 (2022)
Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Whe
Externí odkaz: https://doaj.org/article/0b8a08e7364d4c5baf46b5c7fe2801e9
Zobrazit plný text záznamu
5
Supplemental Figure 1 from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
Autor: Jean E. Lachowicz, Jean-Paul Castaigne, Borhane Annabi, Mustapha Iddir, Jean-Christophe Currie, Simon Lord-Dufour, Sasmita Tripathy, Michel Demeule, Anthony Regina
A. Confirmation of HER2-positive expression status of BT-474 and SKBR3 cells and HER2-negative status of MCF-7, U-87 and HBMEC cells by WB analysis using an anti-HER2 mAb. B. Immunodetection of LRP1 by WB using an antibody directed against the 85 kDa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aaab8dbb02b6e6fc7dc6acfdbf2b914
https://doi.org/10.1158/1535-7163.22502209.v1
Zobrazit plný text záznamu
8
Abstract 3942: Differential expression of a novel transport receptor, SORT1 (sortilin), in cancer versus healthy tissues that can be utilized for targeted delivery of anti-cancer drugs
Autor: Guylaine Roy, Pratik Kadekar, Lynn Marie Douglas, Maude Frappier, Jean-Christophe Currie, Jess Dhillon, Gregory Cesarone, Richard Siderits, Karen Kirchner, Michel Demeule, Christian Marsolais
Publikováno v: Cancer Research. 83:3942-3942
Sortilin (SORT1), or neurotensin receptor-3, is a scavenging receptor in the Vacuolar Protein Sorting 10 protein (Vps10p) family. SORT1 is involved in the internalization and trafficking of its ligands through an endocytic process and is associated w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d35d9dbb1d78196939d5938ee50138db
https://doi.org/10.1158/1538-7445.am2023-3942
Zobrazit plný text záznamu
9
Abstract 4499: The peptide-drug conjugate sudocetaxel zendusortide (TH1902) potentiates anti-tumoral activity of the anti-PD-L1 checkpoint inhibitor and induces immune cell infiltration in a B16-F10 syngeneic melanoma model
Autor: Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Cancer Research. 83:4499-4499
Tumor-infiltrating immune cells are involved in the control of cancer and are closely related to clinical outcomes. Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate (PDC) of the sortilin (SORT1)-binding peptide TH19P01 ester-linked to two
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4cdaa33b4400848c4fa428fec9c7d21d
https://doi.org/10.1158/1538-7445.am2023-4499
Zobrazit plný text záznamu
10
Abstract 4493: Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers
Autor: Cyndia Charfi, Michel Demeule, Jean-Christophe Currie, Alain Zgheib, Bogdan Alexandru Danalache, Richard Béliveau, Christian Marsolais, Borhane Annabi
Publikováno v: Cancer Research. 83:4493-4493
Over the last decade, the targeting of specific cell surface receptors such as human epidermal growth factor receptor 2 (Her2) in breast cancer cells has allowed the emergence of innovative strategies for the delivery of anticancer agents. High expre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a24ce882dd8efb53825e5d1914172b07
https://doi.org/10.1158/1538-7445.am2023-4493
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje